Clinical Trial: Cranberry Juice for Treatment of Urinary Tract Infections

This study is not yet open for patient recruitment.

Sponsored by: National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)

Purpose

The purpose of this study is to determine whether daily consumption of cranberry juice lessens the symptoms and prevents the recurrence of urinary tract infections (UTIs). This study will also determine whether bacteria in the rectal, vaginal, and urethral areas are associated with developing UTIs.

Condition Treatment or Intervention
Urinary Tract Infections
 Drug: Cranberry juice

MedlinePlus related topics:  Urinary Tract Infections

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Cranberry Juice and Urinary Tract Infections

Further Study Details: 

Expected Total Enrollment:  400

Participants in this study will be randomly assigned to consume either 8 ounces of cranberry juice or placebo juice twice a day for 6 months. Participants will have follow-up visits at 3 and 6 months, and whenever they experience a symptomatic episode. Urine, vaginal and rectal specimens will be taken at each visit to test for the presence of bacteria that cause urinary tract infections. Participants will complete a questionnaire at study entry, Day 3, Weeks 1 and 2, and monthly thereafter or whenever there is a recurrence of symptoms.

Eligibility

Ages Eligible for Study:  18 Years   -   40 Years,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

Exclusion Criteria:

  • Other chronic disease
  • Antibiotics within 72 hours prior to study start
  • Hospitalization for any reason within 2 weeks prior to study start
  • Stones in urinary tract
  • Plans to leave Ann Arbor within 6 months after study start
  • Allergy to cranberry or cranberry compounds
  • Pregnancy

Location Information


Michigan
      University of Michigan, Ann Arbor,  Michigan,  48109,  United States
Cibele T. Barbosa-Cesnik  734-764-1350    cibele@umich.edu 

Study chairs or principal investigators

Cibele T. Barbosa-Cesnik,  Principal Investigator,  University of Michigan   

More Information

Study ID Numbers:  R01 AT002086-01
Record last reviewed:  September 2004
Last Updated:  October 13, 2004
Record first received:  September 30, 2004
ClinicalTrials.gov Identifier:  NCT00093054
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005